Judy Dering

5.5k citations

41 papers · 3.6k indexed · 1 hit paper · h-index 23

Oncology top 1%
Molecular Biology top 5%
Pulmonary and Respiratory Medicine top 2%
Cancer Research top 2%
Reproductive Medicine top 2%

Co-authors: Dennis J. Slamon Richard S. Finn Charles Ginther Amrita Desai Ondrej Kalous Dylan Conklin Mohammad Atefi David J. Cohen
Topics: HER2/EGFR in Cancer Research (10 papers)PI3K/AKT/mTOR signaling in cancer (7 papers)Ovarian cancer diagnosis and treatment (6 papers)
Cited by: Oncology Cancer Research Reproductive Medicine
Journals: Journal of Clinical Investigation Journal of Clinical Oncology PLoS ONE
Partner nations: United States United Kingdom Canada

In The Last Decade

Judy Dering

41 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

2009 1.0k citations Richard S. Finn, Judy Dering et al. Breast Cancer Research profile →

Peers

Countries citing papers authored by Judy Dering

Since Specialization

Citations

This map shows the geographic impact of Judy Dering's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judy Dering with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judy Dering more than expected).

Fields of papers citing papers by Judy Dering

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judy Dering. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judy Dering. The network helps show where Judy Dering may publish in the future.

Co-authorship network of co-authors of Judy Dering

This figure shows the co-authorship network connecting the top 25 collaborators of Judy Dering. A scholar is included among the top collaborators of Judy Dering based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judy Dering. Judy Dering is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy 2021 ·PLoS ONE ·Jason J. Zoeller,Michael F. Press,Laura M. Selfors,Judy Dering,Dennis J. Slamon,Sara A. Hurvitz,Joan S. Brugge	8
2	Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures 2016 ·Gynecologic Oncology ·Boris Winterhoff,Habib Hamidi,Chen Wang,Kimberly R. Kalli,Brooke L. Fridley,Judy Dering,(unknown),William A. Cliby,He-Jing Wang,Sean C. Dowdy,Bobbie S. Gostout,Gary L. Keeney,Ellen L. Goode,Gottfried E. Konecny	40
3	Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer 2014 ·JNCI Journal of the National Cancer Institute ·Gottfried E. Konecny,Chen Wang,Habib Hamidi,Boris Winterhoff,Kimberly R. Kalli,Judy Dering,Charles Ginther,(unknown),Sean C. Dowdy,William A. Cliby,Bobbie S. Gostout,Karl C. Podratz,Gary L. Keeney,He-Jing Wang,Lynn C. Hartmann,Dennis J. Slamon,Ellen L. Goode	267
4	Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer 2013 ·Clinical Cancer Research ·Richard S. Finn,Michael F. Press,Judy Dering,Lisa O’Rourke,Allison Florance,Catherine Ellis,Anne‐Marie Martin,Stephen Johnston	20
5	The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth 2013 ·Molecular Cancer Therapeutics ·Edward B. Garon,Richard S. Finn,Habib Hamidi,Judy Dering,Sharon Pitts,Naeimeh Kamranpour,Amrita Desai,Wylie Hosmer,Susan Ide,Emin Avşar,Michael Rugaard Jensen,Cornelia Quadt,Manway Liu,Steven M. Dubinett,Dennis J. Slamon	56
6	A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer 2013 ·Clinical Cancer Research ·Dong‐Joo Cheon,Yunguang Tong,Myung‐Shin Sim,Judy Dering,Dror Berel,Xiaojiang Cui,Jenny Lester,Jessica A. Beach,Mourad Tighiouart,Ann E. Walts,Beth Y. Karlan,Sandra Oršulić	265
7	AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53 2013 ·Breast Cancer Research and Treatment ·Ondrej Kalous,Dylan Conklin,Amrita Desai,Judy Dering,Jennifer B. Goldstein,Charles Ginther,Lee Anderson,Ming Lu,Teodora Kolarova,Mark A. Eckardt,Anita Langerød,Anne‐Lise Børresen‐Dale,Dennis J. Slamon,Richard S. Finn	22
8	Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro 2013 ·Hepatology ·Richard S. Finn,Alexey Aleshin,Judy Dering,Peter Yang,Charles Ginther,Amrita Desai,Danyun Zhao,Erika von Euw,Ronald W. Busuttil,Dennis J. Slamon	43
9	POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer 2013 ·Gynecologic Oncology ·Beth Y. Karlan,Judy Dering,Christine Walsh,Sandra Oršulić,Jenny Lester,Lee Anderson,Charles Ginther,Marlena S. Fejzo,Dennis J. Slamon	75
10	Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer 2013 ·Journal of Thoracic Oncology ·Edward B. Garon,Richard J. Pietras,Richard S. Finn,Naeimeh Kamranpour,Sharon Pitts,Diana C. Márquez‐Garbán,Amrita Desai,Judy Dering,Wylie Hosmer,Erika M. von Euw,Steven M. Dubinett,Dennis J. Slamon	47
11	Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398 in vitro 2012 ·Cancer Research ·Richard S. Finn,(unknown),Danyun Zhao,Lee Anderson,Charles Ginther,Judy Dering,Michael Shi,Diana Graus Porta,(unknown),Dennis J. Slamon	13
12	Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines 2010 ·Molecular Cancer Therapeutics ·Edward B. Garon,Richard S. Finn,Wylie Hosmer,Judy Dering,Charles Ginther,(unknown),Naeimeh Kamranpour,Sharon Pitts,Amrita Desai,David Elashoff,Tim French,Paul D. Smith,Dennis J. Slamon	49
13	Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer 2009 ·Journal of Clinical Oncology ·Richard S. Finn,Michael F. Press,Judy Dering,Michael Arbushites,María Koehler,Cristina Oliva,Lisa S. Williams,Angelo Di Leo	144
14	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitrobreakdown → 2009 ·Breast Cancer Research ·Richard S. Finn,Judy Dering,Dylan Conklin,Ondrej Kalous,David J. Cohen,Amrita Desai,Charles Ginther,Mohammad Atefi,Isan Chen,Camilla Fowst,(unknown),Dennis J. Slamon	1044
15	Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer 2009 ·Breast Cancer Research and Treatment ·Brenda Cohen,Mamiko Shimizu,(unknown),(unknown),(unknown),James Pan,Judy Dering,Michael Reedijk	131
16	Activity of the multikinase inhibitor dasatinib against ovarian cancer cells 2009 ·British Journal of Cancer ·Gottfried E. Konecny,Rickard Glas,Judy Dering,Kanthinh Manivong,Jianfei Qi,Richard S. Finn,(unknown),(unknown),Charles Ginther,Boris Winterhoff,Guolan Gao,Joan S. Brugge,DJ Slamon	81
17	Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer 2008 ·Journal of Clinical Oncology ·Angelo Di Leo,Henry Gómez,Zeba Aziz,Zanete Zvirbule,José Bines,Michael Arbushites,(unknown),María Koehler,Cristina Oliva,Steven H. Stein,Lisa S. Williams,Judy Dering,Richard S. Finn,Michael F. Press	345
18	Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells 2008 ·British Journal of Cancer ·Gottfried E. Konecny,Natarajan Venkatesan,Guangen Yang,Judy Dering,Charles Ginther,Richard S. Finn,Martina Rahmeh,Marlena S. Fejzo,D O Toft,(unknown),Dennis J. Slamon,Karl C. Podratz	92
19	Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro 2007 ·Breast Cancer Research and Treatment ·Richard S. Finn,Judy Dering,Charles Ginther,Cindy Wilson,(unknown),Nishan Tchekmedyian,Dennis J. Slamon	330
20	HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells 2005 ·Breast Cancer Research ·Cindy Wilson,Elaina Cajulis,Jennifer L. Green,(unknown),(unknown),Michael A. Damore,Judy Dering,Frank J. Calzone,Dennis J. Slamon	45

About Judy Dering

Judy Dering is a scholar working on Oncology, Reproductive Medicine and Genetics, having authored 41 papers that have together received 3.6k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (10 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Ovarian cancer diagnosis and treatment (6 papers). The work is most often cited by research in Oncology (2.2k citations), Cancer Research (902 citations) and Reproductive Medicine (343 citations). Judy Dering has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Dennis J. Slamon, Richard S. Finn, Charles Ginther, Amrita Desai, Ondrej Kalous, Dylan Conklin, Mohammad Atefi, David J. Cohen, Camilla Fowst and Isan Chen. Their work appears in journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact